13 insiders reported 47 Form 4 transactions for AN2 Therapeutics, Inc. (ANTX) over the past 18 months (most recent 2026-08-19). Recent activity: Readnour Robin Shane (Director) Sell 16,696 shares, Readnour Robin Shane (Director) Sell 18,706 shares, Zakrzewski Joseph S (Director) Sell 405,880 shares, Aziz Kabeer (Director) Buy 2,852 shares, Martin Patricia A. (Director) Buy 766 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Readnour Robin Shane | Director | Sell | 16,696 | $100,313 |
| 2026-08-19 | Readnour Robin Shane | Director | Sell | 18,706 | $112,389 |
| 2026-08-14 | Zakrzewski Joseph S | Director | Sell | 405,880 | $0 |
| 2026-07-10 | Aziz Kabeer | Director | Buy | 2,852 | $0 |
| 2026-07-10 | Martin Patricia A. | Director | Buy | 766 | $0 |
| 2026-07-10 | Marks Gilbert Lynn | Director | Buy | 2,789 | $0 |
| 2026-07-10 | Eizen Joshua M | See Remarks | Sell | 5,945 | $24,803 |
| 2026-06-02 | Williams Sarah Joanne | Principal Accounting Officer | Sell | 265 | $1,174 |
| 2026-04-10 | Aziz Kabeer | Director | Buy | 3,775 | $0 |
| 2026-04-10 | Martin Patricia A. | Director | Buy | 1,192 | $0 |
| 2026-04-10 | Marks Gilbert Lynn | Director | Buy | 3,775 | $0 |
| 2026-03-05 | Williams Sarah Joanne | Principal Accounting Officer | Sell | 327 | $347 |
| 2026-02-23 | Chanda Sanjay | Chief Development Officer | Buy | 38,000 | $0 |
| 2026-02-23 | Day Lucy | Chief Financial Officer | Buy | 38,000 | $0 |
| 2026-02-23 | Williams Sarah Joanne | Principal Accounting Officer | Buy | 48,375 | $0 |
| 2026-02-23 | Easom Eric | Chief Executive Officer | Buy | 112,250 | $0 |
| 2026-02-23 | Eizen Joshua M | See Remarks | Buy | 50,000 | $0 |
| 2026-01-14 | Marks Gilbert Lynn | Director | Buy | 11,560 | $0 |
| 2026-01-14 | Aziz Kabeer | Director | Buy | 11,560 | $0 |
| 2026-01-14 | Martin Patricia A. | Director | Buy | 3,650 | $0 |
| 2026-01-07 | Day Lucy | Chief Financial Officer | Sell | 3,295 | $3,295 |
| 2026-01-07 | Day Lucy | Chief Financial Officer | Sell | 5,512 | $5,567 |
| 2026-01-07 | Eizen Joshua M | See Remarks | Sell | 17,923 | $17,923 |
| 2026-01-07 | Eizen Joshua M | See Remarks | Sell | 6,931 | $7,000 |
| 2026-01-07 | Prior Stephen David | Chief Strategy Officer | Sell | 3,604 | $3,604 |
Source: SEC Form 4 filings · as of 2026-08-19